immunAware

HLA-A*11:01 | easYmer kit

Product Code:
 
IMM-1018-01
Product Group:
 
MHC Tetramers
Supplier:
 
immunAware
Regulatory Status:
 
RUO
Shipping:
 
Dry Ice
Storage:
 
-20 °C
 

No additional charges, what you see is what you pay! *

CodeSizePrice
IMM-1018-01-05050 Tests£956.00
Quantity:
IMM-1018-01-100100 Tests£1,220.00
Quantity:
IMM-1018-01-150150 Tests£1,749.00
Quantity:
IMM-1018-01-200200 Tests£2,278.00
Quantity:
IMM-1018-01-250250 Tests£2,807.00
Quantity:
IMM-1018-01-300300 Tests£3,336.00
Quantity:
IMM-1018-01-500500 Tests£3,865.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Denmark.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Description:
HLA-Class I easYmer® is a highly active formulation of peptide-receptive HLA class I (HLA-I) molecules (no artificial Cys-bonds linking heavy chain and b2m). Add Peptides of interest to generate specific peptide-HLA class I monomers. The loading efficacy can be validated in a FACS-based bead assay. The monomers can easily be tetramerised with fluorophore-conjugated streptavidin and used to stain cognate T cells for analysis in a flow cytometric assay. The easYmer® technology seamlessly enables: Large-scale production of pMHC monomers with a single epitope for screening a large number of samples, parallel production and screening of pMHC monomers with many different peptide epitope candidates and screening and validation of peptide-HLA-I binding. easYmers® are available in aliquots of 50 Tests (corresponding to 20 ug of pMHC)

References

  • Pavlidis, MA;Viborg, N;Lausen, M;R?n?, B;Kleine-Kohlbrecher, D;; Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens; Frontiers in immunology; 2024; 15():1404121PubMed ID:38720900; DOI: 10.3389/fimmu.2024.1404121; https://www.frontiersin.org/articles/10.3389/fimmu.2024.1404121/full
  • Pulliam, T; et.al.; Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses; Journal for immunotherapy of cancer; 2024; 12(10):PubMed ID:39401968; DOI: 10.1136/jitc-2024-009803; http://dx.doi.org/10.1136/jitc-2024-009803